A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure

BACKGROUND: Erythropoietin stimulating agent (ESA) has been standard of care in treating renal anaemia for the past 20 years. Many patients have limited access to ESA in view of long-term costs leading to suboptimal ESA dosage. Biosimilar epoetin is a potential cost-effective alternative to originat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Soo Kun, Goh, Bak Leong, Visvanathan, Ravindran, Kim, Su Hyun, Jeon, Jin Seok, Kim, Sung Gyun, Chang, Jae Hyun, Lim, Chun Soo, Morad, Zaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620966/
https://www.ncbi.nlm.nih.gov/pubmed/34823497
http://dx.doi.org/10.1186/s12882-021-02601-w

Ejemplares similares

Ejemplares similares